Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 181 to 195 of 1136 results for pain

  1. Pyelonephritis (acute): antimicrobial prescribing (NG111)

    This guideline sets out an antimicrobial prescribing strategy for acute pyelonephritis (upper urinary tract infection) in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.

  2. Urinary tract infection (catheter-associated): antimicrobial prescribing (NG113)

    This guideline sets out an antimicrobial prescribing strategy for catheter-associated urinary tract infection in children, young people and adults. It aims to optimise antibiotic use and reduce antibiotic resistance.

  3. Transaxial interbody lumbosacral fusion for severe chronic low back pain (IPG620)

    Evidence-based recommendations on transaxial interbody lumbosacral fusion for low back pain in adults. This involves removing a damaged disc through a small cut at the base of the spine, and replacing it with an artificial implant.

  4. Relugolix–estradiol–norethisterone for treating symptoms of endometriosis [ID3982]

    In development [GID-TA10873] Expected publication date: TBC

  5. Naloxegol for treating opioid‑induced constipation (TA345)

    Evidence-based recommendations on naloxegol (Moventig) for treating opioid-induced constipation in adults.

  6. Rimegepant for treating migraine (TA919)

    Evidence-based recommendations on rimegepant (Vydura) for the acute treatment of migraine in adults.

  7. Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358)

    Evidence-based recommendations on tolvaptan (Jinarc) for treating autosomal dominant polycystic kidney disease in adults.

  8. Rehabilitation after critical illness in adults (CG83)

    This guideline covers rehabilitation strategies for adults who have experienced a critical illness and stayed in critical care. It aims to improve physical, psychological and cognitive outcomes in people who have been discharged from critical care.

  9. Velmanase alfa for treating alpha-mannosidosis (HST29)

    Evidence-based recommendations on velmanase alfa (Lamzede) for treating alpha-mannosidosis in people under 18 years and in people who turn 18 while on treatment.

  10. The ReCell Spray‑On Skin system for treating skin loss, scarring and depigmentation after burn injury (MTG21)

    Evidence-based recommendations on the ReCell Spray-On Skin system for treating skin loss, scarring and depigmentation after burn injury.

  11. Pressure ulcers: prevention and management (CG179)

    This guideline covers risk assessment, prevention and treatment in children, young people and adults at risk of, or who have, a pressure ulcer (also known as a bedsore or pressure sore). It aims to reduce the number of pressure ulcers in people admitted to secondary or tertiary care or receiving NHS care in other settings, such as primary and community care and emergency departments.

  12. Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip (TA304)

    Evidence-based recommendations on artificial hips and hip resurfacing for treating end-stage arthritis of the hip in adults.

  13. Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (TA223)

    Evidence-based recommendations on cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for treating intermittent claudication in adults with peripheral arterial disease.

  14. Volanesorsen for treating familial chylomicronaemia syndrome (HST13)

    Evidence-based recommendations on volanesorsen (Waylivra) for treating familial chylomicronaemia syndrome in adults.

  15. Upadacitinib for treating active non-radiographic axial spondyloarthritis (TA861)

    Evidence-based recommendations on upadacitinib (Rinvoq) for treating active non-radiographic axial spondyloarthritis in adults.